Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-DC: AAA617 vs Observation in Oligometastatic Prostate Cancer
NCT05939414Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Mar 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 27
01
Overview
A Phase 3 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Novartis. Started Mar 2024; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05939414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939414.